163 related articles for article (PubMed ID: 15468165)
1. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
3. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
4. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
[TBL] [Abstract][Full Text] [Related]
5. IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1.
Fernández M; Sánchez-Franco F; Palacios N; Sánchez I; Cacicedo L
J Mol Endocrinol; 2005 Jun; 34(3):699-712. PubMed ID: 15956341
[TBL] [Abstract][Full Text] [Related]
6. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
7. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Iacopino F; Lama G; Angelucci C; Sica G
Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
11. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
13. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway.
Alleaume C; Eychène A; Harnois T; Bourmeyster N; Constantin B; Caigneaux E; Muller JM; Philippe M
Exp Cell Res; 2004 Oct; 299(2):511-24. PubMed ID: 15350548
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.
Hokari R; Lee H; Crawley SC; Yang SC; Gum JR; Miura S; Kim YS
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G949-59. PubMed ID: 16227528
[TBL] [Abstract][Full Text] [Related]
18. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression.
Yang W; Chen Y; Zhang Y; Wang X; Yang N; Zhu D
Cancer Res; 2006 Feb; 66(3):1320-6. PubMed ID: 16452185
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism.
Rodrigues AR; Pignatelli D; Almeida H; Gouveia AM
Mol Cell Endocrinol; 2009 May; 303(1-2):74-81. PubMed ID: 19428994
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
Collado B; Gutiérrez-Cañas I; Rodríguez-Henche N; Prieto JC; Carmena MJ
Regul Pept; 2004 Jun; 119(1-2):69-75. PubMed ID: 15093699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
